www.hemophilia.ca/coagulation-products
In a decision that surprised many, the U.S. Food and Drug Administration (FDA) last week denied approval of Biomarin’s FVIII gene therapy, branded Roctavian. The...
Three decades of people with hemophilia unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, respectively, has again...
Hemlibra (emicizumab) is indicated in Canada for hemophilia A patients with or without factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the...
Dr. Steven Pipe, Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program in Ann Arbor Michigan, presented an update at the World Federation of...